SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/264143"
 

Search: onr:"swepub:oai:gup.ub.gu.se/264143" > Early Recurrence an...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Paciaroni, M. (author)

Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • Ovid Technologies (Wolters Kluwer Health),2017

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/264143
  • https://gup.ub.gu.se/publication/264143URI
  • https://doi.org/10.1161/jaha.117.007034DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background-The optimal timing to administer non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated the rates of early recurrence and major bleeding (within 90 days) and theirtiming in patients with acute ischemic stroke and atrial fibrillation who received NOACs for secondary prevention. Methods and Results-Recurrence was defined as the composite of ischemic stroke, transient ischemic attack, and symptomatic systemic embolism, and major bleeding was defined as symptomatic cerebral and major extracranial bleeding. For the analysis, 1127 patients were eligible: 381 (33.8%) were treated with dabigatran, 366 (32.5%) with rivaroxaban, and 380 (33.7%) with apixaban. Patients who received dabigatran were younger and had lower admission National Institutes of Health Stroke Scale score and less commonly had a CHA(2)DS(2)-VASc score >4 and less reduced renal function. Thirty-two patients (2.8%) had early recurrence, and 27 (2.4%) had major bleeding. The rates of early recurrence and major bleeding were, respectively, 1.8% and 0.5% in patients receiving dabigatran, 1.6% and 2.5% in those receiving rivaroxaban, and 4.0% and 2.9% in those receiving apixaban. Patients who initiated NOACs within 2 days after acute stroke had a composite rate of recurrence and major bleeding of 12.4%; composite rates were 2.1% for those who initiated NOACs between 3 and 14 days and 9.1% for those who initiated > 14 days after acute stroke. Conclusions-In patients with acute ischemic stroke and atrial fibrillation, treatment with NOACs was associated with a combined 5% rate of ischemic embolic recurrence and severe bleeding within 90 days.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Agnelli, G. (author)
  • Falocci, N. (author)
  • Tsivgoulis, G. (author)
  • Vadikolias, K. (author)
  • Liantinioti, C. (author)
  • Chondrogianni, M. (author)
  • Bovi, P. (author)
  • Carletti, M. (author)
  • Cappellari, M. (author)
  • Zedde, M. (author)
  • Ntaios, G. (author)
  • Karagkiozi, E. (author)
  • Athanasakis, G. (author)
  • Makaritsis, K. (author)
  • Silvestrelli, G. (author)
  • Lanari, A. (author)
  • Ciccone, A. (author)
  • Putaala, J. (author)
  • Tomppo, L. (author)
  • Tatlisumak, TurgutGothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology(Swepub:gu)xtatlt (author)
  • Abdul-Rahim, A. H. (author)
  • Lees, K. R. (author)
  • Alberti, A. (author)
  • Venti, M. (author)
  • Acciarresi, M. (author)
  • D'Amore, C. (author)
  • Becattini, C. (author)
  • Mosconi, M. G. (author)
  • Cimini, L. A. (author)
  • Soloperto, R. (author)
  • Masotti, L. (author)
  • Vannucchi, V. (author)
  • Lorenzini, G. (author)
  • Tassi, R. (author)
  • Guideri, F. (author)
  • Acampa, M. (author)
  • Martini, G. (author)
  • Sohn, S. I. (author)
  • Marcheselli, S. (author)
  • Mumoli, N. (author)
  • De Lodovici, M. L. (author)
  • Bono, G. (author)
  • Furie, K. L. (author)
  • Tadi, P. (author)
  • Yaghi, S. (author)
  • Toni, D. (author)
  • Letteri, F. (author)
  • Tassinari, T. (author)
  • Kargiotis, O. (author)
  • Lotti, E. M. (author)
  • Flomin, Y. (author)
  • Mancuso, M. (author)
  • Maccarrone, M. (author)
  • Giannini, N. (author)
  • Bandini, F. (author)
  • Pezzini, A. (author)
  • Poli, L. (author)
  • Padovani, A. (author)
  • Scoditti, U. (author)
  • Denti, L. (author)
  • Consoli, D. (author)
  • Galati, F. (author)
  • Sacco, S. (author)
  • Carolei, A. (author)
  • Tiseo, C. (author)
  • Gourbali, V. (author)
  • Orlandi, G. (author)
  • Giuntini, M. (author)
  • Chiti, A. (author)
  • Giorli, E. (author)
  • Gialdini, G. (author)
  • Corea, F. (author)
  • Ageno, W. (author)
  • Bellesini, M. (author)
  • Colombo, G. (author)
  • Monaco, S. (author)
  • Baronello, M. M. (author)
  • Karapanayiotides, T. (author)
  • Caso, V. (author)
  • Göteborgs universitetInstitutionen för neurovetenskap och fysiologi (creator_code:org_t)

Related titles

  • In:Journal of the American Heart Association: Ovid Technologies (Wolters Kluwer Health)6:122047-9980

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view